Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Diana I. Albu, Jiayi Wu, Kuan-chung Huang, Renee Wright-Michaud, Shanqin Xu, Galina Kuznetsov, Xingfeng Bao and Mary Woodall-Jappe | ||||||||||||
Title | Abstract B198: Pharmacological profile of the PGE2 EP4 receptor antagonist E7046 | ||||||||||||
|
|||||||||||||
URL | http://mct.aacrjournals.org/content/14/12_Supplement_2/B198.short | ||||||||||||
Abstract Text | Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B198 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
E7046 | AN0025|E-7046|E 7046 | AN0025 (E7046) is a small molecule inhibitor of E2 receptor type 4 (EP4), which may result in antitumor activity including inhibition of cell proliferation and reduced tumor growth (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B198, PMID: 32554609). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|